5/5/1 mg/ml semaglutide A new study conducted by leading researchers across the United States suggests GLP-1s could have a much greater impact beyond obesity. Follow the link in our bio for more on the study Semaglutide / Cyanocobalamin Injection |

Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells

doi: 10.1111/j.1651-2227.1994.tb13461.x

Semaglutide commonly causes gastrointestinal side effects including nausea, vomiting, and diarrhea, particularly during the initial weeks of treatment or following dose increases

In 2025, the American Association of Clinical Endocrinology updated its Obesity Algorithm, which highlights the importance of preserving skeletal muscle during medical weight-loss interventions: patients who retain strength tend to experience fewer side effects, more energy, and better long-term weight maintenance

Do not push through severe symptoms

2011;300:C1421